Evidence map›Paper›PMID 38805302›Full record

ArticleThe Journal of clinical investigation2024

Induced CD8α identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation.

Celia C Cubitt, Pamela Wong, Hannah K Dorando, Jennifer A Foltz, Jennifer Tran, Lynne Marsala, Nancy D Marin, Mark Foster, Timothy Schappe, Hijab Fatima and 9 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Safety and Feasibility of InfusingbioRxiv : the preprint server for biology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Celia C CubittDivision of Oncology, Siteman Cancer Center, and.
Pamela WongDivision of Oncology, Siteman Cancer Center, and.
Hannah K DorandoDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Jennifer A FoltzDivision of Oncology, Siteman Cancer Center, and.
Jennifer TranDivision of Oncology, Siteman Cancer Center, and.
Lynne MarsalaDivision of Oncology, Siteman Cancer Center, and.
Nancy D MarinDivision of Oncology, Siteman Cancer Center, and.
Mark FosterDivision of Oncology, Siteman Cancer Center, and.
Timothy SchappeDivision of Oncology, Siteman Cancer Center, and.
Hijab FatimaDivision of Allergy, Immunology and Rheumatology, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Michelle Becker-HapakDivision of Oncology, Siteman Cancer Center, and.
Alice Y ZhouDivision of Oncology, Siteman Cancer Center, and.
Kimberly HwangDivision of Oncology, Siteman Cancer Center, and.
Miriam T JacobsDivision of Oncology, Siteman Cancer Center, and.
David A Russler-GermainDivision of Oncology, Siteman Cancer Center, and.
Emily M MaceDivision of Allergy, Immunology and Rheumatology, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
Melissa M Berrien-ElliottDivision of Oncology, Siteman Cancer Center, and.
Jacqueline E PaytonDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.
Todd A FehnigerDivision of Oncology, Siteman Cancer Center, and.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic LeukemiaP50CA171963 · NCI · WASHINGTON UNIVERSITY · PI Daniel C Link · 2013 to 2026
$31.6M
PRE-AND POSTGRADUATE TRAINING IN MOLECULAR HEMATOLOGYT32HL007088 · NHLBI · WASHINGTON UNIVERSITY · PI Grant Anthony Challen, Stephen Oh · 1985 to 2026
$14.1M
Washington University Paul Calabresi K12 Career Development Award for Clinical OncologyK12CA167540 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio, Ramaswamy Govindan · 2012 to 2026
$11.7M
TRANSLATING NK CELL BIOLOGY INTO CLINICAL CANCER IMMUNOTHERAPYR01CA205239 · NCI · WASHINGTON UNIVERSITY · PI FEHNIGER, TODD A · 2017 to 2020
$2.4M
Postdoctoral Training Program in Genomic MedicineT32GM139799 · NIGMS · WASHINGTON UNIVERSITY · PI DICKSON, PATRICIA I · 2021 to 2025
$817k
Mechanism of CD8 regulation of natural killer cell biologyF30AI161318 · NIAID · WASHINGTON UNIVERSITY · PI CUBITT, CELIA CLAIRE · 2021 to 2024
$152k
Elucidating the role of EOMES in Memory-Like NK cell DifferentiationF31GM146361 · NIGMS · WASHINGTON UNIVERSITY · PI TRAN, JENNIFER · 2022 to 2024
$90k
NCI NIH HHS K12 CA167540NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA171963NCI NIH HHS R01 CA205239NHLBI NIH HHS T32 HL007088NIAID NIH HHS F30 AI161318NIGMS NIH HHS F31 GM146361NIGMS NIH HHS T32 GM139799
6 · The paper itself

Abstract

The surface receptor CD8α is present on 20%-80% of human (but not mouse) NK cells, yet its function on NK cells remains poorly understood. CD8α expression on donor NK cells was associated with a lack of therapeutic responses in patients with leukemia in prior studies, thus, we hypothesized that CD8α may affect critical NK cell functions. Here, we discovered that CD8α- NK cells had improved control of leukemia in xenograft models compared with CD8α+ NK cells, likely due to an enhanced capacity for proliferation. Unexpectedly, we found that CD8α expression was induced on approximately 30% of previously CD8α- NK cells following IL-15 stimulation. These induced CD8α+ (iCD8α+) NK cells had the greatest proliferation, responses to IL-15 signaling, and metabolic activity compared with those that sustained existing CD8α expression (sustained CD8α+) or those that remained CD8α- (persistent CD8α-). These iCD8α+ cells originated from an IL-15Rβhi NK cell population, with CD8α expression dependent on the transcription factor RUNX3. Moreover, CD8A CRISPR/Cas9 deletion resulted in enhanced responses through the activating receptor NKp30, possibly by modulating KIR inhibitory function. Thus, CD8α status identified human NK cell capacity for IL-15-induced proliferation and metabolism in a time-dependent fashion, and its presence had a suppressive effect on NK cell-activating receptors.

Indexed as

CD8 AntigensCell ProliferationInterleukin-15Killer Cells, NaturalLymphocyte ActivationHumansCD8 antigen, alpha chainCD8 AntigensIL15 protein, humanInterleukin-15CancerImmunologyInnate immunityNK cells

Identifiers

PMID38805302
PMCPMC11291271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.